Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 8;13:905651. doi: 10.3389/fimmu.2022.905651

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Guo, Yang, He, Sun, Song and Qu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Network meta-analysis for different PD-1 inhibitor combination treatments. (A) Hazard ratio (HR) [95% credible intervals (CI)] for overall survival (OS) and progression-free survival (PFS). (B) Relative risk (RR) (95% CI) for ORR and ≥3 TRAEs. (C) Hazard ratio (HR) [95% credible intervals (CI)] for overall survival (OS) of CPS ≥1. Data in each cell are HR or RR (95% CI) for the comparison of row-defining treatment versus column-defining treatment. HR less than 1 and RR for ORR more than 1 favored upper-row treatment. RR for ≥3 TRAEs more than 1 favored downer-row treatment. Significant results were highlighted in red and bold. Niv+L-OHP, nivolumab plus oxaliplatin-based chemotherapy; Sin+L-OHP, sintilimab plus oxaliplatin-based chemotherapy; Pem+DDP, pembrolizumab plus cisplatin-based chemotherapy; L-OHP, oxaliplatin-based chemotherapy; DDP, cisplatin-based chemotherapy.